Makes matched sets of heart procedure tools that hospitals cannot build by mixing parts from different suppliers.
At a glance
- Depends onUpstream position: supplies 4 industries, depends on 0
- ScaleMarket cap is above the global median
Makes matched sets of heart procedure tools that hospitals cannot build by mixing parts from different suppliers.
What this company is and how it runs — written from structure, not news.
Merit Medical Systems makes the inflation devices and guide catheters used in cardiac catheterization procedures, and calibrates their pressure ratings and dimensional tolerances against each other during the same production run in cleanrooms at South Jordan, Utah and Galway, Ireland. Because that calibration happens during manufacturing rather than afterward, a competitor that makes only catheters or only inflation devices cannot claim the matched-pair performance specification without replicating both product lines, their shared tooling, and a separate FDA 510(k) clearance covering the combination. Once a catheterization laboratory adopts a particular kit, switching suppliers means revalidating the entire procedural kit — not just swapping one part — and FDA rules prevent hospitals from legally mixing components from different manufacturers' cleared systems, so even a cheaper single component from a rival cannot be plugged in. The arrangement holds together as long as the FDA's 510(k) pathway treats the matched pair as a unit; if regulators begin requiring clinical evidence of matched-pair performance the way Europe's Medical Device Regulation now does, every cleared configuration would need new clinical data, and the link between the existing tooling validation and the regulatory standing that makes switching so difficult would break.
How does this company make money?
The company sells single-use interventional devices directly to hospitals and through medical distributors, charging per unit. Individual catheters and inflation devices are priced separately, and bundled procedural kits that combine both carry their own pricing — so a hospital buying a complete kit pays a different rate than one purchasing components individually.
What makes this company hard to replace?
Interventional physicians build physical technique habits around specific catheter shaft flexibility and tip shapes, and switching to a different configuration requires retraining. Hospital value analysis committees cannot simply swap one component — they must revalidate the entire procedural kit when changing suppliers, which is a significant administrative and clinical burden. FDA rules prevent hospitals from legally combining components from different manufacturers' kit systems, so even if a cheaper single component existed elsewhere, it could not be plugged into an existing cleared kit.
What limits this company?
Adding a new catheter size or tip shape requires building new manufacturing tooling and going through a separate FDA 510(k) clearance process for each one. Expanding the cleanrooms in South Jordan or Galway triggers a full re-inspection of the facility's quality controls. Volume within already-cleared product configurations can grow, but adding new configurations is slow because each regulatory approval must be completed one at a time and cannot be run in parallel.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance pathways for interventional devices, which are the legal gate for every product it ships. It relies on medical-grade PTFE and polyurethane polymers that meet USP Class VI biocompatibility standards, ethylene oxide sterilization infrastructure, ISO 13485-certified cleanroom facilities, and tungsten and platinum alloys used to make catheter components visible on imaging.
Who depends on this company?
Interventional cardiologists performing angioplasty would face shortages of both inflation devices and guide catheters if this company stopped supplying them. Hospital catheterization laboratories would lose access to the bundled procedural kits built for specific procedures, and would not be able to reassemble equivalent kits from other suppliers' parts. Interventional radiologists performing embolization — a procedure that cuts off blood supply to tumors — would lose access to the specialized microcatheters designed to reach tumor blood vessels.
How does this company scale?
Catheter extrusion and injection molding can be run at higher volumes within the existing cleanroom capacity without major new investment, so producing more of an already-cleared product is relatively straightforward. What does not get cheaper or faster as the company grows is the tooling: every catheter diameter and tip configuration has its own set of manufacturing tools that must be separately validated, and those fixed costs stay in place no matter how many units are made.
What external forces can significantly affect this company?
Medicare reimbursement rates for cardiac catheterization procedures set the ceiling on what hospitals are willing to spend on interventional supplies, so a rate cut shrinks purchasing budgets directly. The European Medical Device Regulation is already requiring clinical evidence for products that were previously approved under older rules, which could force costly re-submissions across the European product portfolio. Aging populations in developed markets mean more procedures are needed, but cost-containment pressure from health systems works in the opposite direction, pushing down spending per procedure.
Where is this company structurally vulnerable?
If FDA changed the 510(k) approval standard for interventional kit systems to require clinical trial evidence proving that the matched pair works as claimed — the way Europe's Medical Device Regulation has already done retroactively — every existing cleared kit would need new clinical data to stay on the market. That would break the link between the production tooling and the regulatory approval that makes the matched kit a defensible product, effectively forcing the entire portfolio back through a much harder approval process.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph